Victoria P. Johnson, Michael Gekhtman, Olga M. Kuznetsova
{"title":"Pocock和Simon协变量自适应随机化研究中时间到事件终点检验的有效性","authors":"Victoria P. Johnson, Michael Gekhtman, Olga M. Kuznetsova","doi":"10.1080/19466315.2023.2261672","DOIUrl":null,"url":null,"abstract":"AbstractRandomization procedures that enforce balance in prognostic factors, most commonly stratified randomization, are often employed in clinical trials. When the number of factors or factor levels is large, dynamic allocation procedures, such as the Pocock and Simon’s covariate-adaptive randomization (minimization) are preferred. In their ground-breaking work Ye and Shao (2020) identified two classes of covariate-adaptive randomization procedures. They have demonstrated theoretically that for these classes, when the model is misspecified, the robust score test (Lin and Wei, 1989) as well as the unstratified log-rank test used for analysis of time-to-event endpoints, are valid or conservative (Ye and Shao, 2020). This fact, however, was not established for minimization other than through simulations of survival endpoints. In this paper, we point out that the results of Ye and Shao can be expanded to a more general class of randomization procedures. We show, in part theoretically, in part through simulations of the within-strata imbalances, that minimization belongs to this class. Along the way we describe the asymptotic correlation matrix of the normalized within-stratum imbalances following minimization with equal prevalence of all strata. We expand the robust tests proposed by Ye and Shao for stratified randomization to minimization and examine their performance through simulations.Keywords: minimizationType I errorrobust survival analysis testsDisclaimerAs a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also. AcknowledgementsThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors would like to thank the anonymous reviewers whose recommendations substantially improved the paper.FundingThe author(s) reported there is no funding associated with the work featured in this article.","PeriodicalId":51280,"journal":{"name":"Statistics in Biopharmaceutical Research","volume":"22 1","pages":"0"},"PeriodicalIF":1.5000,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Validity of tests for time-to-event endpoints in studies with the Pocock and Simon covariate-adaptive randomization\",\"authors\":\"Victoria P. Johnson, Michael Gekhtman, Olga M. Kuznetsova\",\"doi\":\"10.1080/19466315.2023.2261672\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"AbstractRandomization procedures that enforce balance in prognostic factors, most commonly stratified randomization, are often employed in clinical trials. When the number of factors or factor levels is large, dynamic allocation procedures, such as the Pocock and Simon’s covariate-adaptive randomization (minimization) are preferred. In their ground-breaking work Ye and Shao (2020) identified two classes of covariate-adaptive randomization procedures. They have demonstrated theoretically that for these classes, when the model is misspecified, the robust score test (Lin and Wei, 1989) as well as the unstratified log-rank test used for analysis of time-to-event endpoints, are valid or conservative (Ye and Shao, 2020). This fact, however, was not established for minimization other than through simulations of survival endpoints. In this paper, we point out that the results of Ye and Shao can be expanded to a more general class of randomization procedures. We show, in part theoretically, in part through simulations of the within-strata imbalances, that minimization belongs to this class. Along the way we describe the asymptotic correlation matrix of the normalized within-stratum imbalances following minimization with equal prevalence of all strata. We expand the robust tests proposed by Ye and Shao for stratified randomization to minimization and examine their performance through simulations.Keywords: minimizationType I errorrobust survival analysis testsDisclaimerAs a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also. AcknowledgementsThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors would like to thank the anonymous reviewers whose recommendations substantially improved the paper.FundingThe author(s) reported there is no funding associated with the work featured in this article.\",\"PeriodicalId\":51280,\"journal\":{\"name\":\"Statistics in Biopharmaceutical Research\",\"volume\":\"22 1\",\"pages\":\"0\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Statistics in Biopharmaceutical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/19466315.2023.2261672\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MATHEMATICAL & COMPUTATIONAL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistics in Biopharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/19466315.2023.2261672","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
Validity of tests for time-to-event endpoints in studies with the Pocock and Simon covariate-adaptive randomization
AbstractRandomization procedures that enforce balance in prognostic factors, most commonly stratified randomization, are often employed in clinical trials. When the number of factors or factor levels is large, dynamic allocation procedures, such as the Pocock and Simon’s covariate-adaptive randomization (minimization) are preferred. In their ground-breaking work Ye and Shao (2020) identified two classes of covariate-adaptive randomization procedures. They have demonstrated theoretically that for these classes, when the model is misspecified, the robust score test (Lin and Wei, 1989) as well as the unstratified log-rank test used for analysis of time-to-event endpoints, are valid or conservative (Ye and Shao, 2020). This fact, however, was not established for minimization other than through simulations of survival endpoints. In this paper, we point out that the results of Ye and Shao can be expanded to a more general class of randomization procedures. We show, in part theoretically, in part through simulations of the within-strata imbalances, that minimization belongs to this class. Along the way we describe the asymptotic correlation matrix of the normalized within-stratum imbalances following minimization with equal prevalence of all strata. We expand the robust tests proposed by Ye and Shao for stratified randomization to minimization and examine their performance through simulations.Keywords: minimizationType I errorrobust survival analysis testsDisclaimerAs a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also. AcknowledgementsThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors would like to thank the anonymous reviewers whose recommendations substantially improved the paper.FundingThe author(s) reported there is no funding associated with the work featured in this article.
期刊介绍:
Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems.
Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application).
The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review.
Authors can choose to publish gold open access in this journal.